Search
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalMaribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation. … [L39322] Most standard CMV therapies, such as [ganciclovir] or [foscarnet], target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsProducts: Livtencity 200 mg Film Kaplı Tablet (112 (56'lık 2 şişe) Adet)Lysophosphatidic Acid LPA3 Signalling
smpdb.ca/view/SMP0063755SignalingLysophosphatidic acid (LPA) is a water-soluble phospholipid derivative and a potent signalling molecule that binds to six known lysophosphatidic acid receptors (LPARs), named LPA1-LPA6. All six receptors belong to the G protein-coupled r...
Enzymes: Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLasDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesSynonyms: O-desmethylvenlafaxineBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.
Categories: Decreased B Lymphocyte Activation, B Lymphocyte Stimulator-specific InhibitorProducts: BENLYSTIA SC, BENLYSTA 200 MG / 1 MLSelexipag Action Pathway
smpdb.ca/view/SMP0126508Drug actionSelexipag is a non-prostanoid prostacyclin receptor agonist, also known as Uptravi typically used to treat pulmonary arterial hypertension. Selexipag is a selective prostacyclin receptor agonist, it is administered orally and is metaboli...
Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigationalDesogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. … [T521] Desogestrel is now produced semi-synthetically from naturally occurred plant steroids.[F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].
Mixtures: DESOGESTREL E ETINILESTRADIOLO ARISTO, DESOGESTREL E ETINILESTRADIOLO ARISTOCategories: Sex Hormones and Modulators of the Genital System, Cytochrome P-450 SubstratesThrombin
go.drugbank.com/drugs/DB11300ApprovedInvestigationalPatients who are know or suspected to have antibodies to bovine thrombin and/or bovine factor V should not be re-exposed to the product [FDA Label]. … It clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself.
Mixtures: TISSEEL FIBRIN SEALANT VH S/D (FROZEN), ŞTİ.EL LYO 1 ML TROMBIN ÇÖZELTİSİ VE 1 ML FIBRINOJEN ÇÖZELTİSİ ICEREN IKI BILESENLI FIBRIN YAPISTIRICI, SET 1 (2 İĞNE+2 ENJEKTÖR) VE SET 2 (2 İĞNE +2 ENJEKTÖR+1 ENJEKTÖR KLİPSİ+2 BİRLEŞTİRME PARÇASI+ 4Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339] … [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.
Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseSynonyms: Immature tripeptidyl-peptidase I, Immature human tripeptidyl-peptidase 1Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigational[A242432] It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. … While AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13).
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate